UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

 

 

FORM 8-K

 

 

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

June 22, 2016

Date of Report (Date of earliest event reported)

 

 

 

 

 

Cidara Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

 

Delaware

 

001-36912

 

46-1537286

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

6310 Nancy Ridge Drive, Suite 101

San Diego, California

 

92121

(Address of principal executive offices)

 

(Zip Code)

Registrant’s telephone number, including area code: (858) 752-6170

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

On June 22, 2016, Cidara Therapeutics, Inc. (the “Company”) held its 2016 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 25, 2016, the record date for the Annual Meeting, 13,962,747 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.

 

A total of 11,414,189 shares of the Company's common stock were present at the meeting in person or by proxy, which represents approximately 82% of the shares of common stock outstanding as of the record date for the Annual Meeting.

 

Proposal 1. Election of Directors

 

The Company’s stockholders elected the two persons listed below as Class I Directors, each to serve until the Company’s 2019 Annual Meeting of Stockholders and until their successors are duly elected and qualified. The final voting results are as follows:

 

Name

 

Votes For

 

Votes Withheld

 

Broker Non-Votes

Scott M. Rocklage, Ph.D.

10,036,982

 

 

799,129

 

 

578,078

 

Jeffrey Stein, Ph.D.

10,280,211

 

 

555,900

 

 

578,078

 

 

 

Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm

 

The Company’s stockholders ratified the selection of Ernst & Young LLP by the Audit Committee of the Company’s Board of Directors as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016. The final voting results are as follows:

 

 

Votes For

 

Votes Against

 

Abstention

 

Broker Non-Votes

11,414,189

 

 

 

 

 

 

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

 

 

Cidara Therapeutics, Inc.

 

 

 

 

Dated: June 24, 2016

 

 

 

By:

 

/s/ Jeffrey L. Stein

 

 

 

 

 

 

Jeffrey L. Stein

President and Chief Executive Officer

(Principal Executive Officer)